Harry W. Herr

Q: What Schools Are Affiliated With Harry W. Herr

Harry W. Herr is affiliated with the following schools: Medical University of Vienna, University of California, Irvine, Queen's University at Kingston, Cornell University, Columbia University

Harry W. Herr's AcademicInfluence.com Rankings

Harry W. Herr

Medical

#867

World Rank

#1126

Historical Rank

Epidemiology

#107

World Rank

#118

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Harry W. Herr Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Harry W. Herr's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Epidemiology and risk factors of urothelial bladder cancer. (2013) (1625)
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. (2009) (1151)
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. (1992) (694)
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse (1989) (677)
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. (1999) (664)
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. (1985) (623)
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. (1988) (619)
Surgical factors influence bladder cancer outcomes: a cooperative group report. (2004) (564)
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. (1993) (536)
The treated natural history of high risk superficial bladder cancer: 15-year outcome. (1997) (514)
The value of a second transurethral resection in evaluating patients with bladder tumors. (2000) (481)
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma (2007) (464)
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. (2015) (450)
Cystectomy for bladder cancer: a contemporary series. (2001) (441)
Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? (2001) (390)
Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. (1999) (361)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. (2003) (338)
Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care (1994) (336)
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. (1993) (312)
History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. (2008) (308)
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (297)
Superiority of ratio based lymph node staging for bladder cancer. (2003) (288)
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. (1995) (284)
Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. (2004) (281)
Bladder cancer. Clinical practice guidelines in oncology. (2005) (278)
Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer (2008) (272)
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. (2014) (272)
Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. (1988) (271)
Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. (2000) (268)
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. (1990) (263)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. 1 1 H. Barton Grossman, M.D (2002) (260)
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. (2008) (254)
Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. (2001) (251)
Complications following radical cystectomy for bladder cancer in the elderly. (2009) (249)
Penile cancer: relation of extent of nodal metastasis to survival. (1987) (241)
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. (2002) (239)
Urachal Carcinoma: A Clinicopathologic Analysis of 24 Cases With Outcome Correlation (2009) (239)
Complications after radical cystectomy: analysis of population-based data. (2006) (238)
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. (2009) (234)
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (230)
Intermittent endocrine therapy for advanced prostate cancer (1986) (229)
Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. (1986) (228)
Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. (1989) (226)
Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. (2007) (223)
Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. (2001) (216)
Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. (2000) (211)
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. (1987) (208)
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma (1987) (203)
Defining optimal therapy for muscle invasive bladder cancer. (2007) (200)
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. (1988) (199)
Adult urological sarcoma. (1992) (198)
Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. (2001) (196)
Quality control in transurethral resection of bladder tumours (2008) (196)
Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. (1999) (195)
A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder (2008) (194)
Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. (2005) (191)
Conservative management of muscle-infiltrating bladder cancer: prospective experience. (1987) (189)
Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. (2004) (189)
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. (1994) (189)
An overview of intravesical therapy for superficial bladder tumors. (1987) (188)
A comparison of white‐light cystoscopy and narrow‐band imaging cystoscopy to detect bladder tumour recurrences (2008) (185)
Quality of life of incontinent men after radical prostatectomy. (1994) (184)
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. (1986) (183)
Defining bacillus Calmette-Guerin refractory superficial bladder tumors. (2003) (183)
Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. (1992) (182)
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. (1998) (181)
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. (2018) (180)
Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. (2003) (178)
The National Cancer Data Base report on bladder carcinoma (1996) (175)
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. (2007) (174)
Influence of smoking status on the disease‐related outcomes of patients with tobacco‐associated superficial transitional cell carcinoma of the bladder (1999) (173)
Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. (2018) (169)
Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. (1997) (166)
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. (2008) (162)
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. (2011) (157)
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. (1996) (156)
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. (1999) (152)
The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. (2014) (148)
Clinical stage I testis cancer: long-term outcome of patients on surveillance. (1998) (147)
Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. (2001) (147)
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. (2004) (147)
Male urethral carcinoma: analysis of treatment outcome. (1999) (145)
A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy (1993) (141)
Penile cancer: Clinical Practice Guidelines in Oncology. (2013) (139)
Surgery for a post-chemotherapy residual mass in seminoma. (1997) (137)
CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. (1997) (136)
Urachal carcinoma: contemporary surgical outcomes. (2007) (135)
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. (1996) (134)
Adherence to surveillance among patients with superficial bladder cancer. (2003) (133)
Effect of intravesical bacillus calmette‐guerin (BCG) on carcinoma in situ of the bladder (1983) (133)
Salvage chemotherapy for patients with germ cell tumors. The memorial sloan‐kettering cancer center experience (1979–1989) (1991) (131)
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? (2009) (129)
Radical cystectomy in the octogenarian. (1997) (127)
VAB-6 combination chemotherapy in disseminated cancer of the testis. (1981) (126)
Management of low grade papillary bladder tumors. (2007) (126)
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. (1992) (126)
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. (1987) (123)
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. (2012) (119)
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? (2007) (119)
Carcinoma in situ of the bladder. (1983) (118)
Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors. (1985) (117)
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. (2009) (117)
Impact of a second transurethral resection on the staging of T1 bladder cancer. (2002) (114)
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. (2006) (110)
Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. (1995) (110)
A re‐staging transurethral resection predicts early progression of superficial bladder cancer (2006) (109)
Upper tract tumors in patients with primary bladder cancer followed for 15 years. (1996) (109)
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract (2000) (109)
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. (2019) (108)
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. (1992) (106)
The impact of primary stage on survival in patients with lymph node positive bladder cancer. (1999) (105)
Ethnic differences in bladder cancer survival. (2009) (104)
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. (2003) (104)
The role of ifosfamide plus cisplatin‐based chemotherapy as salvage therapy for patients with refractory germ cell tumors (1990) (104)
High‐dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated (1992) (102)
Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. (2001) (99)
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. (2018) (98)
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. (2008) (98)
Quality of life in prostate cancer patients (1997) (96)
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. (1989) (96)
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. (2019) (96)
Toxicity of intravesical BCG and its management in patients with superficial bladder tumors (1987) (95)
Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. (2004) (94)
Extravesical tumor relapse in patients with superficial bladder tumors. (1998) (94)
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. (2001) (93)
A history of partial nephrectomy for renal tumors. (2005) (92)
Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. (2007) (90)
Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. (1990) (89)
The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. (2001) (86)
Preoperative serum albumin is associated with mortality and complications after radical cystectomy (2014) (86)
Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. (1995) (86)
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. (2005) (86)
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. (1998) (85)
Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. (1998) (83)
Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. (1987) (83)
Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. (1985) (81)
Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. (1991) (81)
Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. (2008) (81)
Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients (2005) (81)
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. (2004) (80)
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. (1997) (80)
Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. (1987) (80)
Pathological response to neoadjuvant chemotherapy for muscle‐invasive micropapillary bladder cancer (2013) (79)
Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. (2004) (78)
Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors (1986) (76)
Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. (2008) (76)
Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. (2012) (76)
Is biopsy of the contralateral testis necessary in patients with germ cell tumors? (1997) (75)
The T1 bladder tumor. (1990) (75)
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. (1996) (74)
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
Urachal carcinoma: the case for extended partial cystectomy. (1994) (74)
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. (2013) (73)
The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. (1994) (73)
Re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. (2017) (72)
Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. (2015) (72)
Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. (2000) (72)
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. (2011) (71)
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. (1995) (70)
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. (2007) (70)
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer (2006) (70)
Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. (2001) (68)
Advanced seminoma: the role of chemotherapy and adjunctive surgery. (1988) (68)
Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. (2006) (68)
Bladder cancer. (2013) (67)
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. (2007) (67)
Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. (1980) (67)
Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? (2004) (65)
Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. (1989) (65)
Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. (1984) (65)
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. (1987) (65)
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. (1995) (64)
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. (2016) (64)
Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. (1994) (63)
Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. (2013) (62)
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. (2000) (62)
Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? (1997) (62)
Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines (2016) (61)
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. (1994) (61)
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. (1997) (61)
Partial nephrectomy for incidental renal cell carcinoma. (1994) (60)
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. (2015) (60)
Can p53 help select patients with invasive bladder cancer for bladder preservation? (1999) (59)
Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. (2011) (58)
Surgical treatment of brain metastases from renal cell carcinoma. (1990) (58)
Renal cell carcinoma in childhood and adolescence: a retrospective survey for prognostic factors in 22 cases. (1996) (57)
The management of clinically unconfirmed positive urinary cytology. (1993) (57)
Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. (2003) (56)
The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. (2017) (55)
Is maintenance Bacillus Calmette-Guérin really necessary? (2008) (55)
Partial nephrectomy for renal cell carcinoma with a normal opposite kidney (1994) (55)
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. (2010) (55)
Narrow‐band imaging cystoscopy to evaluate bladder tumours – individual surgeon variability (2009) (54)
Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship. (2014) (54)
The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. (1990) (53)
Outpatient flexible cystoscopy and fulguration of recurrent superficial bladder tumors. (1990) (53)
Malignancy in uremia: dialysis versus transplantation. (1979) (53)
Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF (2008) (53)
VAB-6 as initial treatment of patients with advanced seminoma. (1985) (53)
Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. (1985) (53)
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. (1988) (52)
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. (2015) (52)
NCCN Urothelial Cancer Practice Guidelines (1998) (52)
Ureteral carcinoma in situ at radical cystectomy: does the margin matter? (1997) (52)
Renal cell carcinoma extending into inferior vena cava. (1983) (51)
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? (2009) (51)
Role of surgery in management of germ cell tumor. (1998) (51)
Safety and efficacy of intravesical bacillus Calmette-Guérin instillations in steroid-treated and immunocompromised patients. (2006) (50)
The risk of urinary tract infection after flexible cystoscopy in patients with bladder tumor who did not receive prophylactic antibiotics. (2015) (50)
Outpatient flexible cystoscopy in men: a randomized study of patient tolerance. (2001) (50)
Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer (2006) (49)
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) (49)
Updated concepts and treatment of carcinoma in situ. (1998) (49)
Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder (2007) (47)
Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi‐Institutional Cohort Study (2018) (47)
Transurethral resection and intravesical therapy of superficial bladder tumors. (1991) (46)
Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. (2002) (46)
Max Nitze, the cystoscope and urology. (2006) (46)
Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. (1996) (46)
Routine CT scan in cystectomy patients: does it change management? (1996) (45)
Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? (1999) (45)
Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. (1990) (45)
Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. (2013) (45)
The concept of lymph node density--is it ready for clinical practice? (2007) (45)
Flow cytometry of normal and nonneoplastic diseases of the bladder: an estimate of the false positive rate. (1982) (45)
Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. (2002) (44)
Reflex UroVysion testing in suspicious urine cytology cases (2009) (44)
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. (2011) (44)
Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. (1999) (43)
Presacral cystic schwannoma in a man. (2003) (42)
Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? (2015) (42)
Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. (2012) (42)
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. (2006) (42)
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. (2013) (42)
Role of Re-Resection in Non–Muscle-Invasive Bladder Cancer (2011) (41)
Henoch-Schönlein purpura associated with cancer of prostate. (1982) (41)
Intermittent catheterization in neurogenic bladder dysfunction. (1975) (41)
Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality) (2003) (41)
Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. (1987) (40)
P53 nuclear overexpression and disease progression in ta-bladder carcinoma. (1993) (39)
Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. (2015) (39)
Paternity in men with stage I testis tumors on surveillance. (1998) (39)
Surgical factors in the treatment of superficial and invasive bladder cancer. (2005) (38)
Staging invasive bladder tumors (1992) (38)
A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. (2016) (37)
Clinical outcome of primary versus secondary bladder carcinoma in situ. (2010) (37)
Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. (2013) (37)
Fertility and testis cancer. (1993) (36)
Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. (2011) (36)
Impact of smoking on outcomes after intravesical bacillus Calmette–Guérin therapy for urothelial carcinoma not invading muscle of the bladder (2011) (36)
Radiographic versus pathologic size of renal tumors: implications for partial nephrectomy. (2001) (36)
Clinical value of transurethral second resection of bladder tumor: systematic review. (2014) (35)
Preoperative accuracy of diagnostic evaluation of the urachal mass. (2012) (35)
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. (1997) (35)
Preoperative irradiation with and without chemotherapy as adjunct to radical cystectomy. (1985) (35)
Bladder cancer, version 3.2020 (2020) (34)
HLA antigens in patients with germ cell cancers of the testis. (1982) (34)
Management of inguinal lymph nodes in patients with testicular tumors following orchiopexy, inguinal or scrotal operations. (1973) (32)
Prognostic significance of regional lymph node histology in cancer of the bladder. (1976) (32)
Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin. (1989) (32)
Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. (2001) (31)
Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture. (1976) (31)
Surgical management of renal tumors: a historical perspective. (2008) (31)
Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. (2014) (31)
Outpatient urological procedures in antibiotic‐naive patients with bladder cancer with asymptomatic bacteriuria (2012) (31)
Bladder cancer. Clinical guidelines in oncology. (2006) (30)
NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. (1998) (30)
Narrow‐band imaging cystoscopy to evaluate the response to bacille Calmette‐Guérin therapy: preliminary results (2010) (30)
Should we abandon the FISH test? (2007) (30)
Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence. (1994) (30)
Role of Repeat Resection in Non-Muscle-Invasive Bladder Cancer. (2015) (30)
Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice. (1984) (30)
Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? (2009) (30)
Carboplatin, etoposide, and bleomycin for patients with poor‐risk germ cell tumors (1990) (29)
Interstitial radiation: short-term palliation or curative therapy? (1985) (29)
VP‐16–213 and cisplatin in the treatment of patients with refractory germ cell tumors (1984) (29)
Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. (2012) (29)
Risk factors and predictors of severity score and complications of pediatric hemorrhagic cystitis. (2014) (29)
Natural history of positive urinary cytology after radical cystectomy. (2006) (29)
Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma. (1988) (29)
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift? (2011) (29)
Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. (1994) (28)
Residual mass after chemotherapy for seminoma: changing concepts of management. (1987) (28)
Suppressor cells in immunodepressed bladder and prostate cancer patients. (1980) (28)
High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. (1997) (28)
‘Cutting for the stone’: the ancient art of lithotomy (2008) (28)
Flow cytometry followup of patients with low stage bladder tumors. (1982) (28)
Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. (1992) (28)
Pathologic evaluation of radical cystectomy specimens (2004) (27)
Complications of pelvic lymphadenectomy and retropubic prostatic 125I implantation. (1979) (27)
Partial nephrectomy for a renal oncocytoma associated with tuberous sclerosis. (1985) (27)
Management of bladder cancer after renal transplantation. (2013) (27)
Monitoring intravesical bacillus Calmette-Guerin treatment of bladder carcinoma with flow cytometry. (1985) (27)
Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. (1989) (26)
Surgery for Bladder Cancer (2012) (26)
Uncertainty and outcome of invasive bladder tumors. (1996) (26)
Radiation-induced sarcoma following radiotherapy for testicular tumor. (1981) (26)
Automated flow cytometry to monitor intravesical BCG therapy of superficial bladder cancer. (1981) (25)
Fertility status of patients with clinical stage I testis tumors on a surveillance protocol. (1987) (25)
Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. (2001) (25)
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. (2020) (25)
Presumptive downstaging from preoperative irradiation for bladder cancer as determined by flow cytometry: preliminary report. (1983) (25)
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. (1992) (25)
Inguinal lymph node metastases from germ cell testicular tumors. (1984) (25)
Early history of endoscopic treatment of bladder tumors from Grunfeld's polypenkneipe to the Stern-McCarthy resectoscope. (2006) (25)
Pathologic evaluation of radical cystectomy specimens (2002) (24)
Legacy of Edwin Beer: fulguration of papillary bladder tumors. (2005) (24)
Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma (1983) (24)
A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. (2015) (24)
Management of teratoma. (1993) (23)
Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection (2013) (23)
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (2019) (23)
Phase II Trial of Pyrazoloacridine as Second-Line Therapy for Patients with Unresectable or Metastatic Transitional Cell Carcinoma (2000) (23)
Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder (2017) (23)
INTRATUMORAL HETEROGENEITY OF ERBB2 AMPLIFICATION AND HER2 EXPRESSION IN MICROPAPILLARY UROTHELIAL CARCINOMA: MP48‐03 (2017) (23)
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. (2010) (23)
Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. (2009) (22)
Characterization of bladder papilloma by two-parameter DNA-RNA flow cytometry. (1982) (21)
Preservation of sexual potency in prostatic cancer patients after pelvic lymphadenectomy and retropubic 125I implantation. (1979) (21)
Phase I trial of α-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer (1986) (21)
Intravesical therapy. A critical review. (1987) (21)
Robotic radical cystectomy--is the diversion the Achilles' heel? (2014) (21)
Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors. (1991) (21)
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. (1994) (21)
Editorial: Uncertainty, Stage and Outcome of Invasive Bladder Cancer (1994) (20)
Idiopathic retroperitonial fibrosis misinterpreted as lymphoma by computed tomography. (1979) (20)
Urothelial neoplasms in pediatric and young adult patients: A large single-center series. (2017) (20)
Epidermoid cysts of the testis: role of conservative surgery. (1985) (19)
Adjuvant vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum chemotherapy regimen with and without maintenance in patients with resected stage IIB testis cancer. (1982) (19)
Monitoring endoscopic treatment of superficial bladder carcinoma by postoperative urinary cytology. (1987) (18)
Surgery of invasive bladder cancer: is pathologic staging necessary? (1990) (18)
A plea for a uniform surveillance schedule after radical cystectomy. (2011) (18)
Bladder carcinosarcoma: histologic variation in metastatic lesions. (1983) (18)
The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group. (1990) (18)
Franklin, Lavoisier, and Mesmer: origin of the controlled clinical trial. (2005) (17)
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation. (1990) (17)
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. (2006) (17)
Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder. (1985) (17)
Urinary diversion practice patterns among certifying American urologists. (2012) (17)
A comparison of hospital-based charges following partial and radical nephrectomy. (2002) (17)
A proposed simplified staging system of invasive bladder tumors. (1993) (17)
Lipogranulomatosis of external genitalia. (1974) (16)
Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). (2012) (16)
Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion? (2017) (16)
Optimizing outcomes at every stage of bladder cancer: do we practice it? (2009) (16)
Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. (2021) (16)
Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. (2003) (16)
Interstitial Irradiation in Prostatic Cancer: Report of 10-Year Results (1987) (16)
Uncertainty, stage and outcome of invasive bladder cancer. (1994) (15)
Narrow-Band Imaging Evaluation of Bladder Tumors (2014) (15)
Radiographic vs surgical size of renal tumours after partial nephrectomy (2000) (15)
Immediate versus delayed outpatient flexible cystoscopy: final report of a randomized study. (2001) (15)
pT1 bladder cancer. (1991) (15)
Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience (2014) (15)
Conservative management of renal adenoma v. adenocarcinoma. (1981) (14)
Bladder cancer: Pelvic lymphadenectomy revisited (1988) (14)
Fibrosarcoma associated with intensive chemotherapy for advanced germ cell testicular tumor (1983) (14)
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. (2016) (14)
Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. (1991) (14)
Progression of T1 bladder tumors (1999) (14)
Evaluation of new resectoscope loop for transurethral resection of bladder tumors. (1998) (14)
Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC) (2007) (14)
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial (2022) (14)
Immunobiolqgy of Human Bladder Cancer (1976) (14)
Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder. (1978) (14)
Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. (1982) (14)
Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma (2010) (13)
Regionalization of radical cystectomy in the United States. (2017) (13)
Selection of testicular tumor patients for omission of retroperitoneal lymph node dissection. (1986) (13)
Point: effect of radiation-associated second malignancies on prostate cancer survival. (2008) (13)
Extent of pelvic lymph node dissection during radical cystectomy: where and why! (2010) (13)
Radical cystectomy and orthotopic urinary reconstruction in patients with bladder cancer after renal transplantation: clinical outcomes and description of technique. (2013) (13)
Urethral injuries in the Civil War. (2005) (12)
Neoadjuvant chemotherapy for invasive bladder cancer. (1989) (12)
Intravesical bacille Calmette-Guerin in patients with asymptomatic bacteriuria. (2011) (12)
Adherence to surveillance guidelines after radical cystectomy: a population-based analysis. (2014) (12)
Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients. (2013) (12)
Transurethral resection in regionally advanced bladder cancer. (1992) (12)
Bladder cancer. (2009) (12)
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063) (2017) (12)
Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC). (2016) (11)
Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy: A Prospective Randomized Controlled Trial. (2020) (11)
Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectomy. (1991) (11)
Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer. (2009) (11)
Urological injuries in the Civil War. (2004) (11)
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma (1999) (11)
274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder (2004) (11)
Trends in Management and Outcomes Among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. (2020) (11)
Long Term Survival in Advanced Urothelial Cancer with M-VAC: The First Two Years of Accrual (1987) (11)
Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience. (1990) (11)
Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology. (1987) (10)
Screening urine analysis before bacille Calmette‐Guérin instillation does not reduce the rate of infectious complications (2012) (10)
Localized squamous cell carcinoma of the bladder causing hypercalcemia and inhibition of PTH secretion. (1998) (10)
Use of prophylactic antibiotics in the high-risk patient undergoing prostatectomy: effect on morbidity. (1973) (10)
Commentary: Does Asymptomatic Bacteriuria Reduce the Risk of Recurrence of Non-muscle-invasive Bladder Tumors? (2016) (10)
Orbital metastases from prostatic carcinoma. (1982) (10)
PERCIVALL POTT, THE ENVIRONMENT AND CANCER (2011) (10)
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy (2011) (10)
Pseudocyst of pancreas simulating a renal neoplasm. (1975) (10)
Hemosiderosis of urinary bladder. (1979) (10)
Interstitial irradiation using I-125 seeds. (1987) (9)
Adherent suppressor cells in the blood of patients with bladder cancer. (1981) (9)
Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer. (1986) (9)
Optimal combined modality treatment improves outcome of locally advanced bladder cancer: Analysis of SWOG 8710 (2005) (9)
Ureteropyeloscopy: the diagnostic and therapeutic approach to upper tract urothelial tumors (1985) (9)
The integration of chemotherapy and surgery for bladder cancer. (2005) (9)
Re: Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. (1987) (9)
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma (2021) (9)
THE IMPACT OF POSTOPERATIVE COMPLICATIONS ON THE TIMING OF ADJUVANT CHEMOTHERAPY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR INVASIVE OR NODE POSITIVE BLADDER CANCER (BCa) (2008) (9)
Does current chemotherapy improve survival of patients with invasive bladder cancer? (1997) (8)
Predictors and oncological outcomes following positive surgical margins at partial nephrectomy (2009) (8)
Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. (2014) (8)
Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract. (2006) (8)
Ignorance is bliss: the Listerian revolution and education of American surgeons. (2007) (8)
Intravesical therapy. (1992) (8)
Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette–Guérin? (2020) (8)
Importance of wide re‐resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution (2018) (7)
Office-based management of nonmuscle invasive bladder cancer. (2013) (7)
Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma. (1983) (7)
Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. (2009) (7)
Bladder biopsy of normal-appearing mucosa is not helpful in patients with unexplained positive cytology after nonmuscle invasive bladder cancer. (2015) (7)
Re: Derya Tilki, Oliver Reich, Pierre I. Karakiewicz, et al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol 2010;58:112-7. (2010) (7)
Hodgkin's disease of the prostate: a detailed case report. (1986) (7)
CRYOPRESERVATION OF HUMAN EFFECTOR CELLS ACTIVE IN ANTIBODY‐DEPENDENT CELL‐MEDIATED CYTOTOXICITY (1976) (7)
Bladder cancer: advances in biology and treatment. (1994) (7)
Association of primary germ cell tumor of the testis and renal cell carcinoma. (1993) (7)
Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy (2019) (7)
Improving the quality of operative reports for transurethral resection of bladder tumor surgery in resident education. (2017) (7)
Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC). (2016) (7)
Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy. (2020) (7)
External sphincterotomy in traumatic and non-traumatic neurogenic bladder dysfunction. (1975) (7)
Consideration for treatment of upper urinary tract tumors with topical therapy. (1986) (6)
Clinical Downstaging After Neo-Adjuvant M-VAC for Transitional Cell Carcinoma of the Urothelium (1987) (6)
Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. (2018) (6)
Perirenal lipoma versus renal cell carcinoma. (1991) (6)
Sclerosing mesenteritis associated with skin panniculitis and pleural thickening. (1999) (6)
Immunobiology of human bladder cancer. (1976) (5)
Flow cytometry in urologic oncology. (1986) (5)
Primary urethral cancer: treatment patterns and associated outcomes (2020) (5)
Editorial comment on: robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience. (2008) (5)
Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell (non-TCC) carcinomas of the urothelial tract. (2006) (5)
Pelvic sarcoma causing gynecomastia. (1990) (5)
Urine cytology after flexible cystoscopy (2005) (5)
433 EFFICACY AND SAFETY OF MYCOBACTERIAL CELL WALL DNA COMPLEX IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG (2011) (5)
Summary of effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder (by Harry W. Herr, MD, Carl M. Pinsky, MD, Willet F. Whitmore, Jr, MD, Herbert F. Oettgen, MD, and Myron R. Melamed, MD). 1983. (1997) (5)
829: A Restaging Transurethral Resection Predicts Early Progression of Superficial Bladder Cancer (2006) (5)
Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function. (1978) (5)
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. (1994) (5)
1650 PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MYCOBACTERIAL CELL WALL-DNA COMPLEX IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG (2011) (5)
M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium. (1988) (5)
Low risk bladder tumors--less is more! (2008) (5)
Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes Following Radical Cystectomy. (2019) (5)
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. (2020) (5)
Ganglioneuroma arising in accessory adrenal gland. (1980) (5)
Preventable Cancer Deaths Associated with Bladder Preservation for Muscle Invasive Bladder Cancer. (2019) (4)
Cystoscopy and intravesical bacille Calmette–Guérin therapy in antibiotic-naïve patients with bladder cancer with asymptomatic bacteriuria: An update (2016) (4)
Complete vertical cleft of the glans penis. (1972) (4)
Effect of estrogen on the mixed lymphocyte reaction in normal individuals and prostatic cancer patients (1982) (4)
Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Pro. (2011) (4)
Long-term results of bcg therapy : Concern about upper tract tumors (1998) (4)
LBA-17 MULTICENTER PROSPECTIVE PHASE II CLINICAL TRIAL OF GEMCITABINE AND CISPLATIN AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA (2019) (4)
The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum (2018) (4)
Panniculectomy in conjunction with radical cystectomy in the obese patient. (1983) (4)
Major surgery and scleromyxedema. (1984) (4)
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. (2014) (3)
Suppressor cell activity in lymph nodes regional to bladder carcinoma. (1977) (3)
Reduced Recurrence of Low-grade Papillary Bladder Tumors Associated With Asymptomatic Bacteriuria. (2019) (3)
NMP22 and surveillance for recurrent bladder cancer. (2006) (3)
Urethral stricture disease: experience with patch graft urethroplasty. (1980) (3)
Immune reactivity of lymph nodes regional to prostatic cancer. (1978) (3)
Predicting the metastatic potential of prostatic cancer: Is lymph node staging necessary? (1987) (3)
Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. (2022) (3)
Perioperative intravesical therapy: effective treatment, unfulfilled promises. (2009) (3)
Chemotherapeutic management of invasive bladder carcinoma. (1988) (3)
Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients. (2020) (3)
1571: Adjuvant Intravesical Therapy and Improved Survival Among Elderly Patients with Superficial Bladder Cancer (2007) (3)
Conservative management following clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: Contemporary outcomes of a multi-institutional prospective cohort study. (2018) (3)
Is radical radiotherapy effective in patients with pT1G3 NXM0 bladder cancer? (2008) (3)
Untreated hypernephroma of thirty-three years. (1993) (3)
Prognostic risk factors in low stage testicular germ cell tumors (1998) (3)
Mixed leukocyte culture reactivity of lymph node cells regional to transitional cell carcinoma of the bladder. (1978) (3)
Urologic Principles Define the Standards for Successful Bladder Preservation in Muscle-invasive Bladder Cancer. (2019) (3)
Androgen stimulated chemotherapy in the dunning R-3327 prostatic adenocarcinoma (2004) (2)
The role of surgery in initial staging and follow up. (1990) (2)
Carcinoma in situ of the bladder. (1995) (2)
PI-01 PROGRESSION FROM NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) TO MUSCLE INVASION IS ASSOCIATED WITH LOWER RESPONSE RATES TO NEOADJUVANT CHEMOTHERAPY (2016) (2)
“Immunostaging” patients with malignant disease (1975) (2)
Re: Rethinking Screening for Breast Cancer and Prostate Cancer (2010) (2)
Immunotherapy of bladder tumors. (1984) (2)
Role of Etoposide-Based Chemotherapy in the Treatment of Patients With Refractory or Relapsing Germ Cell Tumors (1985) (2)
33: Complications Following Radical Cystectomy: Population Based Data (2006) (2)
Narrow Band Cystoscopy (2015) (2)
ONCOLOGIC OUTCOMES FOR PATIENTS WITH POSITIVE SURGICAL MARGINS AT PARTIAL NEPHRECTOMY (2008) (2)
Orchiectomy alone in clinical stage A disease (1984) (2)
Rectal invasion by benign prostatic hyperplasia. (1977) (2)
Is less radical cystectomy better, and how can we be sure? (2005) (2)
Reply to Donald L. Lamm and Nilay M. Gandhi's letter to the editor re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85. (2014) (2)
MP55-04 PARTIAL CYSTECTOMY POST NEOADJUVANT CHEMOTHERAPY: MEMORIAL SLOAN-KETTERING CANCER CENTER CONTEMPORARY EXPERIENCE (2014) (2)
Bladder Cancer , Version 5 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk (2022) (2)
Accuracy of the Extent of Bladder Cancer Nodal Metastases Found at Pelvic Lymphadenectomy at the Time of Cystectomy: Relation to Primary Tumor Stage (2010) (2)
852: Biological Behavior of Bladder Cancer in Patients Previously Treated with Radiation for Prostate Cancer (2005) (1)
Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma. (1997) (1)
Effect of irradiation on the immunocompetence of peripheral blood and regional lymph node lymphocytes in bladder cancer. (1980) (1)
Editorial comment. (2009) (1)
Association of single-nucleotide polymorphisms in BCL2L1 and TACC3 with response to bacillus Calmette-Guérin intravesical therapy in non-muscle-invasive bladder cancer. (2012) (1)
Suprapubic approach for bilateral orchiectomy and placement of testicular prostheses. (1990) (1)
PD34-12 IMPORTANCE OF WIDE RE-RESECTION IN ADULT SPERMATIC CORD SARCOMAS: REPORT ON ONCOLOGIC OUTCOMES AT A SINGLE INSTITUTION (2016) (1)
Primary or pseudohyperparathyroidism? (1973) (1)
Intratumoral heterogeneity of ERBB2/HER2 expression in micropapillary urothelial carcinoma. (2017) (1)
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. (2022) (1)
Interstitial irradiation for localized prostate cancer. (1983) (1)
Presumptive Downstaging From Preoperative Irradiation for Bladder Cancer as Determined by Flow Cytometry: Preliminary Report (1983) (1)
From Galen's Urine to Harvey's Blood. (2017) (1)
Narrow Band Imaging for Urothelial Cancer (2015) (1)
Retraction notice to "Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors": Eur Urol 67 (2015) 605-608. (2016) (1)
Hydronephrosis and hydroureter major problem in patients with spinal cord injury. (1973) (1)
Does difluoromethylornithine prevent recurrence in low-risk superficial bladder cancer? (2007) (1)
847: Prospective Evaluation of P53 as a Prognostic Marker in T1 Transitional Cell Carcinoma (TCC) of the Bladder (2006) (1)
Intermittent Hormone Therapy for Advanced Prostate Cancer (1987) (1)
2135 CONTEMPORARY MANAGEMENT OF RENAL TRANSPLANT PATIENTS DIAGNOSED WITH UROTHELIAL CARCINOMA OF THE BLADDER (2012) (1)
COUNTERPOINT: Is Immediate Radical Cystectomy Justified When Non-Muscle-Invasive Bladder Cancer First Presents as High-Grade T1 Urothelial Carcinoma on Re-Resection? (2016) (1)
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. (2022) (1)
PD11-10 A 10-ITEM CHECKLIST CHECKLIST IMPROVES REPORTING OF CRITICAL PROCEDURAL ELEMENTS DURING TRANSURETHRAL RESECTION OF BLADDER TUMOR (2016) (1)
Radical Cystectomy and Urinary Diversion after Renal Transplantation: 1866 (2012) (1)
Function of cryopreserved human effector cells in antibody-dependent, cell-mediated cytotoxicity. (1978) (1)
Commentary (Dotan/Herr): Management of Patients With Muscle-Invasive and Metastatic Bladder Cancer (2005) (1)
1258: Utility of Assessment of Ureteral Margins during Radical Cystectomy for Urothelial Cancer (2006) (1)
Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer. (2015) (1)
History of Transurethral Resection and Fulguration of Bladder Tumors (2018) (1)
Hunter Holmes McGuire and the coffee pot spout procedure. (2007) (1)
Words of Wisdom. Re: use of radical cystectomy for patients with invasive bladder cancer. (2011) (1)
Words of wisdom. Re: Rethinking screening for breast cancer and prostate cancer. (2010) (1)
Effects of intermittent estrogen administration on the R3327H rat prostatic carcinoma (1986) (1)
Cleft glans penis. (1979) (1)
Improving the Quality of Transurethral Resection of Bladder Tumor: Urologist, Audit Thyself. (2020) (1)
NMP22 and surveillance for recurrent bladder cancer. Authors' reply (2006) (1)
MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER (2014) (1)
AGAINST BLADDER SPARING: SURGERY (1999) (1)
Is ‘second-look’ (re-staging) transurethral resection of bladder tumours a new standard of care? (2011) (1)
PD18-08 CAN MUSCLE−INVASIVE BLADDER CANCER BE PREDICTED IN PATIENTS WITH CLINICAL T1 DISEASE? (2014) (1)
MP38-06 COMPARING LONG-TERM ONCOLOGIC OUTCOMES BETWEEN OPEN RADICAL CYSTECTOMY AND ROBOT-ASSISTED LAPAROSCOPIC RADICAL CYSTECTOMY: A RANDOMIZED CLINICAL TRIAL (2016) (1)
Mercury-Induced Necrosis of Murine Renal Cell Carcinoma (1982) (1)
Iodine-125 implantation in the management of localized prostatic carcinoma. (1980) (1)
A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer. (2021) (1)
1512: Age Adjusted Charlson Comorbidity Score is Associated with Treatment Decisions and Clinical Outcomes for Patients Undergoing Radical Cystectomy for Bladder Cancer (2007) (1)
IMPACT OF PREVIOUS RADIOTHERAPY FOR PROSTATE CANCER ON CLINICAL OUTCOMES OF BLADDER CANCER PATIENTS (2009) (1)
Robust Risk Stratification Model Predicts Local-Regional Recurrence After Radical Cystectomy in Different Patient Cohorts (2013) (1)
Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). (2015) (1)
A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors (1989) (1)
Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23. (2008) (1)
Editorial Comment (1991) (1)
MP82-07 TRENDS IN PERIOPERATIVE MANAGEMENT AND OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETECTOMY AT MEMORIAL SLOAN KETTERING CANCER CENTER (2020) (0)
Life of a contract surgeon. (2007) (0)
Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort. (2014) (0)
The evolving role of surgery in the management of renal cell carcinoma. (1989) (0)
MP41-07 LONGITUDINAL QUALITY OF LIFE EVALUATION AFTER RADICAL CYSTECTOMY: RESULTS OF A PROSPECTIVE STUDY (2021) (0)
INFLUENCE OF SMOKING STATUS ON OUTCOMES IN PATIENTS WITH TOBACCO-ASSOCIATED SUPERFICIAL TRANSITIONAL CELL CARCINOMA (TCC) OF THE BLADDER (1999) (0)
Impact of body mass index on quality of surgery and survival outcomes in patients undergoing radical cystectomy for bladder cancer: A Cooperative Group Report (2005) (0)
Legends in urology. (2010) (0)
Letter: "Immunostaging" patients with malignant disease. (1975) (0)
1663: Tnm Nodal Status Versus Lymph Node Density for Prediction of Disease-Specific Survival after Radical Cystectomy for Bladder Cancer (2007) (0)
Editorial comment. (2009) (0)
IS RESTAGING TRANSURETHRAL RESECTION (TUR) NECESSARY IN PATIENTS WITH NON‐MUSCLE INVASIVE BLADDER CANCER (NMIBC) AND FOCAL LAMINA PROPRIA INVASION?: PD48‐01 (2017) (0)
MP38-01 PRIMARY URETHRAL CANCER – TREATMENT PATTERNS AND ASSOCIATED OUTCOMES (2019) (0)
A PROSPECTIVE STUDY ON THE IMPACT OF RADICAL CYSTECTOMY ON SEXUAL FUNCTION IN FEMALES WITH BLADDER CANCER: PD57‐10 (2017) (0)
Uncertainty and Bladder Tumors (1996) (0)
Re: Francesco Montorsi. A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur urol 2007;52:307-9. (2008) (0)
THE IMPACT OF PLASMACYTOID VARIANT HISTOLOGY ON SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER AFTER RADICAL CYSTECTOMY: MP21‐20 (2017) (0)
Pursuing Novel Ideas-Confessions of Lost Opportunities! (2017) (0)
Editorial comment. Patients with low-grade papillary bladder tumors could be monitored safely, deferring therapy unless the recurrent tumors increased in size or number. (2009) (0)
Bedside sphincterometry. (1974) (0)
Nonspecific suppressor cells in peripheral blood of patients with urologic cancers. (1978) (0)
PD66-07 ELECTRONIC RAPID FITNESS ASSESSMENT IDENTIFIES FACTORS ASSOCIATED WITH ADVERSE EARLY POSTOPERATIVE OUTCOMES FOLLOWING RADICAL CYSTECTOMY (2019) (0)
1628 RISK STRATIFICATION FOR LOCAL-REGIONAL FAILURE AFTER CYSTECTOMY (2013) (0)
PHENOTYPIC‐GENOTYPIC CORRELATION OF TP53 AND RB1 IN UROTHELIAL CARCINOMA: MP48‐17 (2017) (0)
Current therapy (2020) (0)
Letter to the editorTo the editor (1973) (0)
Editorial Comments: Apparent Failure of Current Intravesical Chemotherapy Prophylaxis to Influence the Long-Term Course of Superficial Transitional Cell Carcinoma of the Bladder (1995) (0)
PD39-11 THE OUTCOME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER IN THE RETROPERITONEUM (2016) (0)
A RETROSPECTIVE ANALYSIS OF THE EFFECT OF STATIN USE ON THE EFFICACY OF BCG TREATMENT FOR TCC OF THE BLADDER (2008) (0)
Editorial comment. Pelvic lymphadenectomy during robot-assisted radical prostatectomy: assessing nodal yield, perioperative outcomes, and complications. (2009) (0)
Transurethral resection of bladder tumors (2008) (0)
1261: Risk Factors for Development of Metastatic Disease and Death in Female Patients Undergoing Radical Cystectomy (2006) (0)
261: Positive Urine Cytology without Histologic Evidence of Bladder Cancer: Clinical Impact on Recurrent Bladder Cancer and Extra Vesical Sites of Disease (2004) (0)
Recent advances in the immunobiology of human bladder cancer. (1975) (0)
Biological background: definition of high-risk bladder carcinoma: discussion (1997) (0)
328: Accuracy of the Extent of Lymph Node Involvement Found at Pelvic Lymphadenectomy at the Time of Cystectomy in Patients with Bladder Cancer: Relation to Primary Tumor Stage (2004) (0)
Results of high-dose-rate brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for female carcinoma of the urethra (2002) (0)
668 CONTEMPORARY OUTCOMES WITH PRIMARY MALE URETHRAL CARCINOMA (2012) (0)
Association of single-nucleotide polymorphisms in BCL2L1 and TACC3 with response to bacillus Calmette-Guérin intravesical therapy in non-muscle-invasive bladder cancer. (2012) (0)
Review Article IS BIOPSY OF THE CONTRALATERAL TESTIS NECESSARY IN PATIENTS WITH GERM CELL TUMORS (1997) (0)
Renal cell metastases versus liver hemangioma. (1991) (0)
IFOSFAMIDE, PACLITAXEL, AND CISPLATIN (ITP) CHEMOTHERAPY FOR LOCALLY ADVANCED, UNRESECTABLE TRANSITIONAL CELL CARCINOMA OF THE BLADDER (1999) (0)
Case profile: Crossed fused ectopia misdiagnosed as retroperitoneal tumor. (1985) (0)
Reply: To PMID 25623694. (2015) (0)
1245: The Incidence and Risk Factors of Post-Operative Complications in Female Patients Undergoing Radical Cystectomy (2006) (0)
1035 VARIABILITY OF TREATMENT SELECTION AMONG SURGEONS IN PATIENTS WITH CT1 UROTHELIAL CARCINOMA (2010) (0)
Editorial comment. (2012) (0)
MP64-19 THE NATURAL HISTORY OF NON-MUSCLE INVASIVE, NESTED VARIANT OF UROTHELIAL CARCINOMA (2015) (0)
Effects of Intermittent Diet hvIstÃ 1⁄4 bestrol Diphosphate Administration on the R 3327 Rat Prostatic Carcinoma (2006) (0)
Editorial comment. (2010) (0)
1704 THE EFFECT OF REPEAT TRANSURETHRAL RESECTION ON RECURRENCE RATES IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER WHO RECEIVED INTRAVESICAL BACILLUS CALMETTE-GUERIN (2013) (0)
DNA repair capacity and tumor recurrence in patients with non-muscle-invasive bladder cancer (NMIBC). (2013) (0)
Bladder Cancer after Renal Transplantation: 564 (2012) (0)
309: Surgery of Urachal Carcinoma – Evaluation of Long Term Outcome (2004) (0)
Editorial comment. (2010) (0)
848: Predictive Utility of Urinary Cytologies for Non-Transitional Urothelial Malignancies (2005) (0)
Radical transurethral resection (2015) (0)
673 THE IMPACT OF RESTAGING TUR ON OVERALL SURVIVAL IN PATIENTS WITH T1 TCC OF THE BLADDER (2009) (0)
GENOMIC DIFFERENCES BETWEEN “PRIMARY” AND “SECONDARY” MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR NEOADJUVANT CHEMOTHERAPY: MP58‐02 (2017) (0)
Bladder Tumors: Association with Upper Tract Neoplasms (2015) (0)
Comment on: Can Restaging Transurethral Resection of T1 Bladder Cancer Select Patients for Immediate Cystectomy? Authors' reply (2007) (0)
1260: Formulas Estimating Creatinine Clearance are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer (2006) (0)
Male and Female Sexual Function and Dysfunction ; Andrology Re : Evaluating Sexual Function in Women after Radical Cystectomy as Treatment for Bladder Cancer (0)
MP38-07 URETHRAL MELANOMA – CLINICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS (2019) (0)
Reply from Author re: Maurizio Brausi, Salvatore Siracusano. Collateral Activity of Immunotherapy with Bacillus Calmette-Guérin for the Treatment of Non–muscle-invasive Transitional Cell Carcinoma of the Bladder: New Insights. Eur Urol 2013;63:836–7 (2013) (0)
Urine cytology after flexible cystoscopy. Author's replay (2006) (0)
1593 CLINICAL MANAGEMENT OF MUSCLE INVASIVE MICROPAPILLARY BLADDER CANCER (2012) (0)
BCG therapy of superficial bladder tumors. (1989) (0)
1381: Natural History and Clinical Importance of Positive Urinary Cytologies after a Radical Cystectomy for Transitional Cell Carcinoma (2005) (0)
Reply to editorial -- Technologies and traditional skills, Laurence H. Klotz, Can J Urol 2002;9(4):1572-1573. (2002) (0)
Is restaging transurethral resection (TUR) necessary in patients with non-muscle invasive bladder cancer (NMIBC) and focal lamina propria invasion? (2017) (0)
10 RACIAL DISPARITIES IN OUTCOMES AFTER RADICAL CYSTECTOMY (2010) (0)
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy. (1988) (0)
Konventionelle Zystoskopie versus Narrow Band Imaging (2015) (0)
Health Outcomes Research Ethnic Differences in Bladder Cancer Survival (2011) (0)
Retraction notice to "Reply from Author re: Peter C. Black. Narrowing the Cystoscopy Gap. Eur Urol 2015;67:609-10: A Better Transurethral Resection-Proved or Not!": Eur Urol 67 (2015) 610-611. (2016) (0)
PD51-04 BLADDER-SPARING SURGERY (BSS) FOR MUSCLE-INVASIVE BLADDER CANCER (MIBC) AFTER COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY (NAC) (2020) (0)
PD55-01 A PROSPECTIVE SINGLE-BLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL OF PERIOPERATIVE GOAL-DIRECTED FLUID THERAPY VERSUS STANDARD FLUID THERAPY FOR PATIENTS UNDERGOING OPEN RADICAL CYSTECTOMY ON A STANDARDIZED POSTOPERATIVE ENHANCED RECOVERY PATHWAY (2020) (0)
566 IDENTIFICATION OF GENETIC MARKERS ASSOCIATED WITH RESPONSE TO BACILLUS CALMETTE-GUÉRIN INTRAVESICAL THERAPY IN NON-MUSCLE-INVASIVE BLADDER CANCER (2012) (0)
Marı́a José Ribal et al. Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial (2007) (0)
Evaluation of postirradiated prostate biopsy for prostatic carcinoma. (1979) (0)
Reply from Author re: Peter C. Black. Narrowing the cystoscopy gap. Eur Urol 2015;67:609-10: A better transurethral resection--proved or not! (2015) (0)
When is a cystectomy necessary in carcinoma in situ? (1989) (0)
Editorial comment. (2012) (0)
1138 DNA REPAIR CAPACITY AND TUMOR RECURRENCE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2013) (0)
Urological Survey Infection and Inflammation of the Genitourinary Tract Re : Outpatient Urological Procedures in Antibiotic-Naı̈ve Patients with Bladder Cancer with Asymptomatic Bacteriuria (2013) (0)
Commentary (Herr): BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder (1995) (0)
Re: The Concept of Lymph Node Density in Bladder Cancer: Is it Ready for Clinical Practice?: Evaluation of the Relevance of Lymph Node Density in a Contemporary Series of Patients Undergoing Radical Cystectomy (2006) (0)
PROGNOSTIC FACTORS FOR RELAPSE IN PATIENTS WITH LOW VOLUME (pN1) NON-SEMINOMATOUS GERM CELL TUMOR (NSGCT) FOLLOWING PRIMARY RETROPERITONEAL LYMPHADENECTOMY (RPLND) (1999) (0)
Chemotherapy and cystectomy in patients with bladder carcinoma. (1988) (0)
Editorial comment on: External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. (2009) (0)
Differences in somatic DNA damage repair (DDR) gene alterations between primary and secondary muscle invasive bladder cancer (MIBC). (2016) (0)
Ureteroscopic resection of upper tract urothelial tumors (1987) (0)
307: Surgical Variables Impact Bladder Cancer Outcomes. A Cooperative Group Report (2004) (0)
Reply (2009) (0)
Editorial comment. (2009) (0)
Original article Franklin, Lavoisier, and Mesmer: Origin of the controlled clinical trial (2005) (0)
749 Clinical outcome in patients with T1 micropapillary carcinoma of the bladder (2013) (0)
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation for Bladder Cancer (2016) (0)
MP60-16 THREE-MONTH PATIENT-REPORTED OUTCOMES AFTER OPEN VERSUS ROBOTIC RADICAL CYSTECTOMY: A RANDOMIZED CLINICAL TRIAL (2014) (0)
PD9-11 PREDICTORS OF SYMPTOMATIC URETERO-ENTERIC ANASTOMOTIC STRICTURES AFTER RADICAL CYSTECTOMY AND URINARY DIVERSION (2015) (0)
1782 THE ROLE OF IMMEDIATE RADICAL CYSTECTOMY IN THE TREATMENT OF PATIENTS WITH RESIDUAL T1 ON RESTAGING TRANSURETHRAL RESECTION (2012) (0)
1111: The Effect of Body Mass Index (BMI) on the Quality and Morbidity of Radical Cystectomy for Bladder Cancer (2005) (0)
Is Antibacterial Therapy Warranted before Outpatient Flexible Cystoscopy for Bladder Tumor Surveillance? (2019) (0)
TARGETING ERBB2 MUTATIONS IN UROTHELIAL CARCINOMA: MP48‐16 (2017) (0)
486 LYMPH NODE DENSITY: UTILITY IN STRATIFYING PATIENTS FOR ADJUVANT THERAPY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER (2011) (0)
[The role of radiotherapy in locally limited prostate cancer]. (1991) (0)
692 UPPER TRACT IMAGING SURVEILLANCE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER (2013) (0)
407: Time Course of Upper Tract Recurrence Following Radical Cystectomy for Urothelial Cancer (2007) (0)
Unsuspected primary cortical renal cell carcinoma presenting as a metastatic subepithelial pelvic filling defect. (1973) (0)
Narrow Band Imaging in the Evaluation of Upper Tract Urothelial Cancer (2018) (0)
Selecting clinical research projects for the urologic oncologist. (1996) (0)
Extravesical Tumor Relapse in Patients With Superficial Bladder Tumors (1998) (0)
Editorial comment. (2010) (0)
Neoadjuvant Chemotherapy and Bladder-Sparing Surgery for Invasive Bladder Cancer: Ten-Year Outcome (1999) (0)
Defining new standards for adjuvant therapy of testis cancer: a reply. (1996) (0)
Single nucleotide polymorphisms as markers of bacillus Calmette-Guérin intravesical therapy response in non-muscle invasive bladder cancer. (2012) (0)
PD18-01 RADIOGRAPHIC PREDICTORS OF PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA: RESULTS OF A PHASE 2 CLINICAL TRIAL (2020) (0)
1919: CT Urography for Surveillance Following Radical Cystectomy and Urinary Diversion (2004) (0)
Treatment of locoregional germ cell tumor. (1990) (0)
Editorial comment. (2001) (0)
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics (2022) (0)
Effects of a-Difluoromethylornithine and Methylglyoxal Bis(guanylhydrazone) on the Growth of Experimental Renal Adenocarcinoma in Mice1 (2006) (0)
Reply by Authors. (2020) (0)
Previous history of bladder cancer as a prognostic factor for patients diagnosed with transitional cell carcinoma of the upper urinary tract. (2004) (0)
944 RISK AND PREDICTORS OF FRACTURES AFTER RADICAL CYSTECTOMY AND URINARY DIVERSION (2010) (0)
Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
1772 REFLEX FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) ASSAY FOR ATYPICAL URINARY CYTOLOGY IN BLADDER CANCER PATIENTS UNDERGOING SURVEILLANCE CYSTOSCOPY (2013) (0)
Outcome o f P ostchemotherapy S urgery A fter T reatment With M ethotrexate, V inblastine, D oxorubicin, and C isplatin i n P atients W ith U nresectable or M etastatic T ransitional C ell C arcinoma (1999) (0)
AnticarcinomaActivity of Rhodamine123 againsta MurineRenalAdenocarcinoma (1988) (0)
Ureteroenteric Stricture Outcomes: Secondary analysis of an RCT comparing open vs robotic cystectomy. (2022) (0)
PD13-04 REDUCED RECURRENCE OF LOW-GRADE PAPILLARY BLADDER TUMORS ASSOCIATED WITH ASYMPTOMATIC BACTERIURIA (2019) (0)
391 MULTICENTER EVALUATION OF THE ROLE OF UROVYSION FISH ASSAY IN SURVEILLANCE OF PATIENTS WITH BLADDER CANCER: DOES FISH POSITIVITY ANTICIPATE RECURRENCE? (2013) (0)
850: Accuracy of the Extent of Lymph Node Involvement Found at Pelvic Lymphadenectomy at the Time of Radical Prostatectomy in Patients with Prostate Cancer (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Harry W. Herr?

Harry W. Herr is affiliated with the following schools:

Harry W. Herr's Academic­Influence.com Rankings

Why Is Harry W. Herr Influential?

Harry W. Herr's Published Works

Published Works

What Schools Are Affiliated With Harry W. Herr?

Harry W. Herr's AcademicInfluence.com Rankings